同步放化疗与单纯放疗在宫颈浸润癌的近期疗效及安全性

陈洪志; 康华峰; 易春曦; 杨乐

同步放化疗与单纯放疗在宫颈浸润癌的近期疗效及安全性

1. 西安市中心医院肿瘤科
2. 西安交通大学第二附属医院肿瘤科
3. 西安市中心医院耳鼻喉科

基金项目:

基金：陕西省自然科学基金资助项目(2014JM2-8182);

计量
- 文章访问数: 2122
- HTML全文浏览量: 787
- PDF下载量: 27
- 被引次数: 0
出版历程
- 收稿日期: 2016-11-03

Comparison of Efficacy and Safety of Concurrent Radiotherapy and Chemotherapy in Treatment of Invasive Carcinoma of Cervix

Funds:

基金：陕西省自然科学基金资助项目(2014JM2-8182);

摘要

摘要: 目的观察同步放化疗治疗宫颈浸润癌的近期疗效及安全性,探讨其临床价值.方法选择西安市中心医院于2013年1月至2015年3月收治的符合宫颈浸润癌诊断标准患者86例入选本研究,按照数字随机分为2组,每组43例.单纯组术前采取单纯放疗治疗,腔内半量放疗,每次7 Gy,1次/周,总剂量21 Gy×3次;联合组术前采取联合放化疗治疗,腔内剂量21 Gy×3次;顺铂20 mg/m2,放疗第1天开始静滴,连续5 d.2组均于疗程结束2周后行手术治疗,比较2组疗效.结果联合组有效率39例(90.7%),高于单纯组31例(72.1%),P<0.05.联合组宫旁浸润及淋巴结阳性率均低于单纯组,P<0.05.2组治疗期间白细胞降低、恶心、呕吐、腹泻及肝肾功能异常发生率比较差异无统计学意义(P>0.05);联合组脱发21例(48.8%),高于单纯组0例(0.0%),P<0.05.结论同步放化疗治疗宫颈浸润癌的近期疗效较佳,宫旁浸润及淋巴结阳性率更低,但脱发发生率更高,具有重要临床价值.
- 同步放化疗 /
- 宫颈癌 /
- 近期疗效 /
- 淋巴结
Abstract: Objective To observe the safety and efficacy of concurrent radiotherapy and chemotherapy in the treatment of invasive carcinoma of cervix, and to evaluate its clinical value. Methods We selected 86 patients treated in our hospital in January 2013-2015 year in March according to the diagnostic criteria of invasive cervical cancer in this study, and randomly divided them into two groups, with 43 cases in each group. The simple group was given single radiotherapy before operation, including half amount of radiotherapy in the the cavity, 7Gy each time, 1time/week, total dose of 21 Gy * 3 times. The combined group was given preoperative radiotherapy and chemotherapy, including 21 Gy * 3 times of radiotherapy, and intravenous instillation of 20 mg/m2 of cisplatin for continuous 5 days form the first day of radiotherapy. Patients in both groups were given surgical treatment 2 weeks after single radiotherapy or combined radiotherapy and chemotherapy, then the curative effects of two groups were compared. Results The effective rate of combined group was 90.7%(39 cases) and was higher than that of simple group 72.1%(31 cases)(P<0.05). The parametrial invasion and lymph node positive rate in the combined group was lower than that in the simple group(P<0.05). There was no statistically significant difference in the white blood cell decrease,the incidence of nausea, vomiting, diarrhea and abnormal liver and kidney function between two groups(P>0.05). The hair loss rate in the combined group was 48.8%(21 cases),which was higher than the simple group(0 %)(P<0.05). Conclusion Concurrent chemotherapy in the treatment of cervical cancer infiltration is better, the infiltration and lymph node positive rate is lower, but the incidence of hair loss is higher,so it has important clinical value.
- Concurrent radiotherapy and chemotherapy /
- Cervical cancer /
- Short-term effect /
- Lymph node

HTML全文

参考文献(15)

[1]	[1]BONANNO L,ZAGO G,MARULLI G,et al.Radiological response and survival in locally advanced non-small-cell lung cancer patients treated with three-drug induction chemotherapy followed by radical local treatment[J].Onco Targets Ther,2016,21(9):3671-3681.
[2]徐西伟,黄晓萍,刘巧丹,等.Ⅰb2-Ⅱa期巨块型宫颈癌热疗联合同步放化疗与同步放化疗的疗效比较[J].中山大学学报(医学科学版),2016,37(5):751-756.
[3]汪青松,杨林.根治性子宫切除术联合辅助放疗与同步放化疗治疗宫颈癌比较[J].实用医学杂志,2016,32(23):3886-3889.
[4]赵晶清,赵彩虹,赵妤,等.中晚期宫颈癌患者奈达铂与顺铂联合5-氟尿嘧啶方案同步放化疗疗效及安全性对比分析[J].中国全科医学,2013,16(32):3849-3850,3853.
[5]	[5]POLLOM E L,QIAN Y,DURKEE B Y,et al.Hypofractionated intensity-modulated radiotherapy for patients with non-small-cell lung cancer[J].Clin Lung Cancer,2016,8(9):11-16.
[6]吴琴,张丹,万义学,等.序贯放化疗与同步放化疗对中晚期宫颈癌患者血液学毒性以及肿瘤标志物的影响[J].广西医科大学学报,2017,34(2):288-291.
[7]高平,关小倩,高亚杰,等.奈达铂同步放化疗与顺铂+5-氟尿嘧啶同步放化疗治疗中晚期宫颈癌的疗效和安全性比较[J].中国妇幼保健,2013,28(22):3675-3677.
[8]李芳,朱红卫,张敬,等.同步放化疗对宫颈癌患者生存质量的影响因素分析[J].中国医学装备,2017,14(1):24-27.
[9]孟敏.同步放化疗治疗中晚期宫颈癌的疗效及不良反应[J].中国社区医师,2017,33(6):43-44.
[10]谢小妹,李向阳,殷海涛,等.雷替曲塞联合顺铂同步放化疗治疗中晚期宫颈癌[J].中华妇幼临床医学杂志(电子版),2016,12(6):644-650.
[11]沙红兰,何爱琴.TP方案化疗序贯放疗对宫颈癌术后有高危因素患者的效果观察[J].交通医学,2016,30(6):622-625.
[12]	[12]WANG M,TIAN H,LI G,et al.Significant benefits of adding neoadjuvant chemotherapy before concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma:A meta-analysis of randomized controlled trials[J].Oncotarget,2016,23(25):1158-1163.
[13]李彩红.奈达铂同步放化疗对Ⅰb2~Ⅱb期宫颈癌的治疗作用观察[J].成都医学院学报,2016,11(6):665-671.
[14]	[14]LI N,DOU L,ZHANG Y,et al.The use of sequential endorectal ultrasonography to predict the tumor response of preoperative chemo-radiotherapy in rectal cancer[J].Gastrointest Endosc,2016,25(31):63-69.
[15]范志刚.中晚期宫颈癌同步放化疗临床研究进展[J].实用癌症杂志,2012,27(3):309-311.

相关文章(20)

[1]	严怡然, 沈成万, 尚香玉, 冯婵, 李金秋, 阿仙姑·哈斯木. 高良姜素通过影响Hippo/YAP通路抑制宫颈癌Hela细胞迁移和侵袭, 昆明医科大学学报.
[2]	孟丽燕, 王超群, 陈星慧, 何军晶, 牛雅茹, 马丽莎. 早期宫颈癌术后HPV持续感染的危险因素分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240422
[3]	谢芹, 赵春阳, 张葆溯, 赵洪波. 硫利达嗪抗宫颈癌的潜在作用机制, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220317
[4]	刘洋, 廖婧, 卢又汇, 孙春意, 孟昱时. miR-21负向调控宫颈癌HeLa细胞株中hTERT的表达, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210307
[5]	张娟, 张红芸. 宫颈管搔刮术在宫颈癌筛查中的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210822
[6]	谭丁及, 尹洪莉, 朱锐, 张曦, 余鑫, 飞勇, 李昕, 段铭, 何亮, 杨宏英. 宫颈上皮内瘤变和宫颈癌患者的阴道微生态特点, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210821
[7]	卿清, 刘洋, 周红林. 宫颈癌筛查策略的研究进展, 昆明医科大学学报.
[8]	周栩茹, 王熙, 田洁, 谢玲玲, 许宏宇, 李晓兰. 黏附斑激酶在宫颈癌组织中表达及意义, 昆明医科大学学报.
[9]	杨琳琳. 高危子宫内膜癌术后辅助同步放化疗与单纯放疗的临床对比, 昆明医科大学学报.
[10]	杨琳琳. 检测外周血CA125对同步放化疗治疗高危子宫内膜癌的意义, 昆明医科大学学报.
[11]	贾晓霞. DSCT双能量成像碘图在颈部肿大淋巴结中的应用, 昆明医科大学学报.
[12]	蒋美萍. 同步加量调强放射治疗在宫颈癌放疗中的临床观察, 昆明医科大学学报.
[13]	白桦. 同步放化疗与序贯化放疗治疗Ⅲ期不能手术非小细胞肺癌的临床疗效, 昆明医科大学学报.
[14]	魏洁. Twist在中晚期宫颈癌组织中的表达及临床意义研究, 昆明医科大学学报.
[15]	高河云. 淋巴结疾病的彩色多普勒超声诊断价值研究, 昆明医科大学学报.
[16]	高河云. 淋巴结疾病的彩色多普勒超声诊断价值研究, 昆明医科大学学报.
[17]	段鲜盟. 集束化护理对宫颈癌化疗患者效果生活质量及心理状态影响, 昆明医科大学学报.
[18]	刘慧瑾. 宫颈癌组织Vimentin的表达与淋巴转移宫旁浸润的关系研究, 昆明医科大学学报.
[19]	陈永生. 阴茎恶性黑色素瘤并双侧腹股沟淋巴结转移1例报道, 昆明医科大学学报.
[20]	黄雅. Brn-3a、PPAR-γ在宫颈癌及癌前病变中的表达, 昆明医科大学学报.